158 related articles for article (PubMed ID: 19036342)
1. Rosiglitazone modifies HDL structure and increases HDL-apo AI synthesis and catabolic rates.
Carreón-Torres E; Rendón-Sauer K; Monter-Garrido M; Toledo-Ibelles P; Gamboa R; Menjivar M; López-Marure R; Luc G; Fievet C; Cruz D; Vargas-Alarcón G; Pérez-Méndez O
Clin Chim Acta; 2009 Mar; 401(1-2):37-41. PubMed ID: 19036342
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone increases the fractional catabolic and production rates of high-density lipoproteins apo AI in the New Zealand White Rabbit.
Carreón-Torres E; Juárez-Meavepeña M; Cardoso-Saldaña G; Gómez CH; Franco M; Fievet C; Luc G; Juárez-Oropeza MA; Pérez-Méndez O
Atherosclerosis; 2005 Aug; 181(2):233-40. PubMed ID: 16039276
[TBL] [Abstract][Full Text] [Related]
3. [High-density lipoproteins (HDL) size and composition are modified in the rat by a diet supplemented with "Hass" avocado (Persea americana Miller)].
Pérez Méndez O; García Hernández L
Arch Cardiol Mex; 2007; 77(1):17-24. PubMed ID: 17500188
[TBL] [Abstract][Full Text] [Related]
4. Normal HDL-apo AI turnover and cholesterol enrichment of HDL subclasses in New Zealand rabbits with partial nephrectomy.
Toledo-Ibelles P; Franco M; Carreón-Torres E; Luc G; Tailleux A; Vargas-Alarcón G; Fragoso JM; Aguilar-Salinas C; Luna-Luna M; Pérez-Méndez O
Metabolism; 2013 Apr; 62(4):492-8. PubMed ID: 23089050
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin and fenofibrate combination induces the predominance of the large HDL subclasses and increased apo AI fractional catabolic rates in New Zealand white rabbits with exogenous hypercholesterolemia.
Flores-Castillo C; Zamora-Pérez JÁ; Carreón-Torres E; Arzola-Paniagua A; Aguilar-Salinas C; López-Olmos V; Fragoso JM; Luna-Luna M; Rodríguez-Pérez JM; Franco M; Vargas-Alarcón G; Pérez-Méndez Ó
Fundam Clin Pharmacol; 2015 Aug; 29(4):362-70. PubMed ID: 25982284
[TBL] [Abstract][Full Text] [Related]
6. Effects of atorvastatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs.
Briand F; Magot T; Krempf M; Nguyen P; Ouguerram K
Eur J Clin Invest; 2006 Apr; 36(4):224-30. PubMed ID: 16620283
[TBL] [Abstract][Full Text] [Related]
7. Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.
Vrablík M; Dobiásová M; Stulc T; Kasalová Z; Dolezalová R; Prázný M; Fait T; Ceska R
Neuro Endocrinol Lett; 2008 Feb; 29(1):146-50. PubMed ID: 18283261
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients.
van Wijk J; Coll B; Cabezas MC; Koning E; Camps J; Mackness B; Joven J
Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1134-7. PubMed ID: 17184491
[TBL] [Abstract][Full Text] [Related]
9. Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene.
Pérez-Méndez O; Duhal N; Lacroix B; Bonte JP; Fruchart JC; Luc G
Clin Chim Acta; 2006 Jun; 368(1-2):149-54. PubMed ID: 16487502
[TBL] [Abstract][Full Text] [Related]
10. Effect of nandrolone decanonate on paraoxonase activity in hemodialysis patients.
Ghorbanihaghjo A; Argani H; Rahbaninoubar M; Rashtchizadeh N
Clin Biochem; 2005 Dec; 38(12):1076-80. PubMed ID: 16153628
[TBL] [Abstract][Full Text] [Related]
11. Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model.
Sharabi Y; Oron-Herman M; Kamari Y; Avni I; Peleg E; Shabtay Z; Grossman E; Shamiss A
Am J Hypertens; 2007 Feb; 20(2):206-10. PubMed ID: 17261469
[TBL] [Abstract][Full Text] [Related]
12. Suppression of induced atherosclerosis in h-apo AI transgenic mice by overexpression of human apo AI in the aortic wall.
Li H; Gu S; Cao X; Wang Z; She M
Chin Med J (Engl); 2000 Jul; 113(7):657-61. PubMed ID: 11776042
[TBL] [Abstract][Full Text] [Related]
13. Hyperuricemia is Associated with Increased Apo AI Fractional Catabolic Rates and Dysfunctional HDL in New Zealand Rabbits.
Martínez-Ramírez M; Flores-Castillo C; Sánchez-Lozada LG; Bautista-Pérez R; Carreón-Torres E; Fragoso JM; Rodriguez-Pérez JM; García-Arroyo FE; López-Olmos V; Luna-Luna M; Vargas-Alarcón G; Franco M; Pérez-Méndez O
Lipids; 2017 Dec; 52(12):999-1006. PubMed ID: 28940111
[TBL] [Abstract][Full Text] [Related]
14. Induction of bile acid synthesis by cholesterol and cholestyramine feeding is unimpaired in mice deficient in apolipoprotein AI.
Jolley CD; Dietschy JM; Turley SD
Hepatology; 2000 Dec; 32(6):1309-16. PubMed ID: 11093738
[TBL] [Abstract][Full Text] [Related]
15. Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.
Holvoet P; Danloy S; Deridder E; Lox M; Bernar H; Dhoest A; Collen D
J Clin Invest; 1998 Jul; 102(2):379-85. PubMed ID: 9664079
[TBL] [Abstract][Full Text] [Related]
16. Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
Dirican M; Akca R; Sarandol E; Dilek K
J Nephrol; 2004; 17(6):813-8. PubMed ID: 15593056
[TBL] [Abstract][Full Text] [Related]
17. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
[TBL] [Abstract][Full Text] [Related]
18. Effect of fish oil supplements on serum paraoxonase activity in female patients with rheumatoid arthritis: a double-blind randomized controlled trial.
Ghorbanihaghjo A; Kolahi S; Seifirad S; Rashtchizadeh N; Argani H; Hajialilo M; Khabazi A; Alizadeh S; Bahreini E
Arch Iran Med; 2012 Sep; 15(9):549-52. PubMed ID: 22924372
[TBL] [Abstract][Full Text] [Related]
19. The effect of the PPARgamma ligand rosiglitazone on energy balance regulation.
Joosen AM; Bakker AH; Gering MJ; Westerterp KR
Diabetes Metab Res Rev; 2006; 22(3):204-10. PubMed ID: 16110522
[TBL] [Abstract][Full Text] [Related]
20. Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy.
Coll B; van Wijk JP; Parra S; Castro Cabezas M; Hoepelman IM; Alonso-Villaverde C; de Koning EJ; Camps J; Ferre N; Rabelink TJ; Tous M; Joven J
Eur J Pharmacol; 2006 Aug; 544(1-3):104-10. PubMed ID: 16843455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
